Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Susan Kühnast"'
1
Akademický článek
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]
Autor: Sam J.L. van der Tuin, Susan Kühnast, Jimmy F.P. Berbée, Lars Verschuren, Elsbet J. Pieterman, Louis M. Havekes, José W.A. van der Hoorn, Patrick C.N. Rensen, J. Wouter Jukema, Hans M.G. Princen, Ko Willems van Dijk, Yanan Wang
Publikováno v: Journal of Lipid Research, Vol 56, Iss 11, Pp 2085-2093 (2015)
Recently, we showed in APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL cholesterol [(V)LDL-C] rather than by raising HDL cholesterol. Here, we investigated th
Externí odkaz: https://doaj.org/article/703c44bd9c0c4c1b91d3e208489b298a
Zobrazit plný text záznamu
2
Akademický článek
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]
Autor: Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen
Publikováno v: Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of
Externí odkaz: https://doaj.org/article/53e1f0f319af41358683cedf9dce15c4
Zobrazit plný text záznamu
3
Akademický článek
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
Autor: Susan Kühnast, Mieke C Louwe, Mattijs M Heemskerk, Elsbet J Pieterman, Jan B van Klinken, Sjoerd A A van den Berg, Johannes W A Smit, Louis M Havekes, Patrick C N Rensen, José W A van der Hoorn, Hans M G Princen, J Wouter Jukema
Publikováno v: PLoS ONE, Vol 8, Iss 6, p e66467 (2013)
ObjectiveNiacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol. Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-HIGH
Externí odkaz: https://doaj.org/article/7274581cba064ece9f3cedad3694c889
Zobrazit plný text záznamu
4
Variable cartilage degradation in mice with diet-induced metabolic dysfunction : food for thought
Autor: Hans M.G. Princen, R. Kleemann, A.E. Kozijn, Susan Kühnast, Simon C. Mastbergen, F.P.J.G. Lafeber, Harrie Weinans, Reinout Stoop, Lobke Gierman, E.J. Pieterman, R.A. van der Heijden, F. van der Ham, Anne-Marie Zuurmond, A.M. van den Hoek, Martine C. Morrison, A. Van Koppen, I. Bobeldijk, P.M. Stavro, Petra Mulder
Publikováno v: Osteoarthritis and Cartilage, 26(1), 95. W.B. Saunders Ltd
Osteoarthritis and cartilage, 26(1), 95-107. ELSEVIER SCI LTD
Osteoarthritis and Cartilage, 1, 25, 95-107
Objective: Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the mechanisms underlying this metabolic phenotype of OA, we examined cartilage degradation
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b65a74b2fe861890953043093838cf6
https://dspace.library.uu.nl/handle/1874/363420
Zobrazit plný text záznamu
5
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
Autor: J. Wouter Jukema, Petia Doycheva, Anne Tailleux, Susan Kühnast, Ulf Landmesser, Pavani Mocharla, Hans M.G. Princen, Elena Osto, José W.A. van der Hoorn, Bart Staels, Adelheid Kratzer, Branko Simic, Thomas F. Lüscher, Simona Stivala, Margot Crucet, Thimoteus Speer, Hector Giral
Publikováno v: Atherosclerosis, 257, 186-194
Atherosclerosis
Atherosclerosis, 257, 184-194
Background and aims. High-density lipoprotein cholesterol (HDL-C) is inversely related to cardiovascular risk. HDL-C raising ester transfer protein (CETP) inhibitors, are novel therapeutics. We studied the effects of CETP inhibitors anacetrapib and e
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cefeb9d21e9687e743e50842e13b93e
https://www.zora.uzh.ch/id/eprint/150163/
Zobrazit plný text záznamu
6
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials
Autor: Marta Fiocco, Susan Kühnast, J. Wouter Jukema, José W.A. van der Hoorn, Hans M.G. Princen
Publikováno v: European Journal of Pharmacology, 763, 48-63
Non-HDL-cholesterol is well recognised as a primary causal risk factor in cardiovascular disease. However, despite consistent epidemiological evidence for an inverse association between HDL-C and coronary heart disease, clinical trials aimed at raisi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500c6658de8dde80d2c9bc1915060a36
http://hdl.handle.net/1887/108226
Zobrazit plný text záznamu
7
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
Autor: Elsbet J. Pieterman, Ko Willems van Dijk, Sam van der Tuin, Susan Kühnast, Jan B. van Klinken, Thomas F. Lüscher, Louis M. Havekes, Patrick C.N. Rensen, J. Wouter Jukema, Branko Simic, Ulf Landmesser, José W.A. van der Hoorn, Hans M.G. Princen
Publikováno v: European Heart Journal, 1, 36, 39-48
European Heart Journal
European Heart Journal, 36(1), 39-48A
The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and atherosclerosis showing that anacetrapib dose-dependently reduces atherosclerosis development and adds to the anti-atherogenic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d54df54fbd657f7f662b0a589de691
https://doi.org/10.1093/eurheartj/ehu319
Zobrazit plný text záznamu
9
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Autor: Anusch Peyman, Elsbet J. Pieterman, Hans-Ludwig Schäfer, Anita M. van den Hoek, Uwe Schwahn, Susan Kühnast, José W.A. van der Hoorn, Viktoria Gusarova, William J. Sasiela, J. Wouter Jukema, Hans M.G. Princen
Publikováno v: Journal of Lipid Research, 10, 55, 2103-2112
Journal of Lipid Research, 55(10), 2103-2112
Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)
Journal of Lipid Research
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7b3416033f6aa49c622e6e0617ffe8
http://resolver.tudelft.nl/uuid:17ce4754-8fa8-4e08-b529-0e07e5ec7fb3
Zobrazit plný text záznamu
10
Abstract 69: Anacetrapib Dose-dependently Decreases Atherosclerosis Development and Adds to the Beneficial Effects of Atorvastatin in APOE*3Leiden.CETP Mice
Autor: Susan Kühnast, Sam J van der Tuin, Louis M Havekes, Ko Willems van Dijk, Patrick C Rensen, José W van der Hoorn, J W Jukema, Hans M Princen
Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 33
Introduction The residual risk of cardiovascular disease that remains after statin treatment has triggered the search for a secondary treatment target. Epidemiological studies propose HDL-cholesterol (HDL-C) as a possible candidate. Cholesteryl ester
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16e6590eeb3fe961b0624a002057da17
https://doi.org/10.1161/atvb.33.suppl_1.a69
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje